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Primary mediastinal large B-cell lymphoma (PMBL) is a distinct subtype of diffuse large B-
cell lymphoma (DLBCL) that shows overlap with classical Hodgkin lymphoma (CHL) and a 
favorable prognosis compared to mediastinal gray-zone lymphoma (MGZL). We performed 
immunohistochemistry on initial diagnostic specimens of 49 cases of uniformly-treated 
PMBL to determine the frequency and clinical significance of expression of antigens 
commonly seen in CHL and MGZL, along with markers previously shown to be prognostic 
in DLBCL, not otherwise specified. The median age was 37 years with a female:male ratio of 
2.3. After a median follow-up of 78 months, 24% of patients had relapsed or refractory 
disease and 22% had died; the 5-year PFS was 70%. Variable CD15 expression was seen in 
31% of cases, but was not associated with adverse outcome. Hans cell-of-origin, 
proliferation index, and MYC/BCL2 coexpression were not associated with outcome, while 
low PDL1 (p=0.011) and high MUM1 (p=0.065) staining were each associated with shorter 
PFS. A biologic risk score (one point each for low PDL1 and high MUM1) stratified patients 
into three prognostic risk groups for PFS (p=0.001) and OS (p=0.032). On separate 
multivariate models, low PDL1 was independent of R-IPI risk group for PFS (HR 6.0, 
p=0.023), as was a biologic risk score of 2 (HR 5.6, p=0.011). Incorporation of the biologic 
risk score sub-stratified patients within R-IPI groups for both PFS (p<0.001) and OS 
(p<0.001). In summary, we characterize the immunophenotypic spectrum of PMBL and 
identify PDL1 and MUM1 as prognostic biomarkers for high-risk disease. 
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Primary mediastinal (thymic) large B-cell lymphoma (PMBL) is a subtype of diffuse large B-cell 
lymphoma (DLBCL) with distinct clinicopathologic and genetic features. It accounts for 2-4% of 
non-Hodgkin lymphoma and occurs predominantly in young adults with a median age of 35 
years and a female predominance (male:female ratio of 1:2) (1). Patients typically present with a 
bulky mediastinal mass that frequently invades adjacent structures, while involvement of bone 
marrow or non-mediastinal lymph nodes is uncommon at diagnosis (1, 2). 
 
PMBL shares a number of features with classical Hodgkin lymphoma (CHL), particularly the 
nodular sclerosis type. Cases of PMBL often exhibit fibrosis and may contain cells with 
pleomorphic, multilobated nuclei resembling Reed-Sternberg cells and variants, and neoplastic 
cells often express CD30 similar to Reed-Sternberg cells (1). Occasionally, CHL and PMBL 
have been reported together as composite lymphomas or as metachronous tumors in the same 
patient (3). Therefore, it is not surprising that PMBL shares a genetic transcription profile with 
CHL that is distinct from that of DLBCL, not otherwise specified (DLBCL-NOS), with 
activation of the NFκB antiapoptotic survival pathway and the JAK-STAT signaling pathway (4, 
5). Combined expression of the NFκB targets, c-rel and TRAF1, has been found by 
immunohistochemistry in more than 80% of CHL and 50% of PMBL, but only rarely in 
DLBCL-NOS (6, 7). Amplifications in 9p24 resulting in increased JAK-STAT activity and 
upregulation of PDL1 and PDL2, and translocations of CIITA at 16p13 are common in both CHL 
and PMBL; these aberrations involving PDL1, PDL2 and CIITA have been implicated in tumor-
mediated immune evasion in both entities (8, 9). More recently, somatic mutations involving 
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PTPN1 have been identified in both CHL and PMBL, further supporting a biological overlap 
(10). A consequence of this overlap is the existence of cases with morphologic and 
immunophenotypic features intermediate between PMBL and CHL and with shared genetic 
features, termed mediastinal gray-zone lymphoma (MGZL), which is clinically more aggressive 
than either PMBL or CHL (3, 11-16).  
 
The clinical outcome in PMBL appears favorable in comparison to typical DLBCL, but this may 
reflect the tendency of these patients to present with lower-risk features such as young age and 
limited stage (4). The most commonly employed first-line treatment regimen for PMBL 
historically has been R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisone), usually combined with radiation therapy due to the bulky, localized nature of this 
disease. However, multiple retrospective studies in the pre-rituximab era suggested that CHOP is 
inferior to more intensive regimens in PMBL, and only limited retrospective and prospective 
data in the modern era support the benefit of rituximab when added to CHOP chemotherapy (17-
22). In addition, a recent retrospective analysis from the Massachusetts General Hospital (MGH) 
of 63 adult PMBL patients treated with R-CHOP +/- radiation therapy demonstrated a high rate 
of primary refractory disease (23). Similar high rates of treatment failure have been reported in 
pediatric patients (12). Unfortunately, the cure rate for progressive disease after initial treatment 
is low. A recent prospective study of dose-adjusted R-EPOCH (rituximab, etoposide, prednisone, 
vincristine, cyclophosphamide, and doxorubicin) was associated with a high response rate in 
PMBL (24), but this intense regimen may be unnecessary in some patients. These findings point 
to the need for improved prognostic biomarkers in PMBL, in order to identify patients who may 
benefit from higher intensity regimens or novel treatment approaches. 
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We have encountered occasional cases of morphologically typical PMBL that express antigens 
commonly seen in CHL or MGZL, such as CD15, but that do not fulfill 2008 WHO criteria for a 
diagnosis of MGZL (16). The prevalence and clinical significance of such findings in PMBL is 
unknown. Therefore, we sought to investigate the prognostic significance of expression of a 
CHL or MGZL-like immunophenotype in PMBL, along with the significance of expression of 
antigens related to cell-of-origin, proliferation, apoptosis, and immune evasion that have 
previously been shown to have prognostic significance in DLBCL-NOS (25-28), with a focus on 






Following Partners HealthCare Institutional Review Board approval with waiver of patient 
consent (protocol # 2007P001458, last approval 1/25/2016), we performed a computer-assisted 
search of the MGH pathology files and clinicopathologic database of hematologic malignancies 
for all cases of PMBL treated with R-CHOP with or without radiation therapy. Patients were 
identified based on a combination of clinical and pathological criteria, including a large B-cell 
lymphoma presenting in the anterior mediastinum as the dominant site of disease with typical 
pathological features of PMBL on tissue biopsy (1). Only patients who had completed therapy 
and with sufficient pre-treatment biopsy tissue for tissue microarray (TMA) construction and/or 
further immunohistochemical analysis were included, yielding a total of 49 cases diagnosed 
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between 1996 and 2012. Of these, 41 patients had been included in a prior study in which 
clinical features and outcome, but not correlation with histopathologic features, were previously 
reported (23); however, inclusion in the prior analysis was not a selection criterion for inclusion 
in the current study.  
 
TMA Construction and Immunohistochemical Analysis 
 
TMAs were manually constructed using 2 mm diameter tissue cores of tumor cell-rich 
representative areas of lymphoma in cases with sufficient tissue, with inclusion of cores of 
reactive lymphoid control tissue. In five cases with limited tissue, selected immunohistochemical 
stains were performed on whole-tissue sections and evaluated in tumor cell-rich areas. 
Immunohistochemistry was performed on 5 µm formalin- or B-plus-fixed, paraffin-embedded 
tissue sections using an automated immunostainer (BOND-III, Leica Biosystems, Buffalo Grove, 
IL). Briefly, sections were deparaffinized, antigen retrieval was performed with an EDTA-based 
solution (Leica) at pH 9, and sections were stained with antibodies to pan-B-cell antigens, CHL-
associated antigens, and antigens previously shown to have prognostic significance in DLBCL-
NOS (Supplemental Table 1). All of the antibodies used in the study are available at our 
institution for clinical diagnosis and have been validated for both formalin and B-plus fixatives 
with comparable staining results. 
 
Immunohistochemical stains were evaluated independently by two authors (JRB and ARS) who 
were blinded to patient outcome, with resolution of scoring discrepancies via consensus review. 
For MYC and Ki67, percent staining of neoplastic lymphoid cells was estimated in deciles. PD1 
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staining of background small lymphocytes was scored as positive or negative, with any staining 
considered positive. For all other antibodies, scores were assigned for staining intensity (0 = no 
staining, 1+ = weak staining, 2+ = moderate staining, 3+ = strong staining) and percentage of 
lymphoma cells staining (0: 0%, 1+: 1-25%, 2+: 26-50%, 3+: 51-75%, 4+: >75%). Staining 
intensity and frequency scores were multiplied to yield an overall H-score ranging from 0-12, 
which was categorized as follows: no staining (0), weak/focal or low overall staining (1-3) and 
moderate/strong/diffuse or high overall staining (4-12). Interobserver agreement for antibody 




Descriptive statistics were used to characterize patients at baseline. Ann Arbor stage was 
determined from baseline radiology reports or from documentation in the medical record by the 
primary oncologist. Tumor characteristics, including type and number of extranodal sites of 
disease, were included in the analysis only where documented in baseline radiology reports. 
Primary endpoints were overall survival (OS), defined as time from initial diagnosis until death 
from any cause, censoring at time last known alive for patients still alive, and progression-free 
survival (PFS), defined as time from initial diagnosis until disease progression or death, 
censoring at time last known alive and disease-free for patients alive without progressive disease. 
OS and PFS curves were obtained using the Kaplan-Meier method with 95% confidence 
intervals calculated using Greenwood’s formula. Univariate analysis was performed to assess 
predictors of outcome and tested for significance using the log-rank test. Multivariable Cox 
proportional hazards models were used to estimate hazard ratios with confidence intervals. 
Page 7 of 27
John Wiley & Sons
American Journal of Hematology












Univariate and multivariable recursive partitioning classification analyses were performed to 
identify significant prognostic factors for time-to-event outcomes. Wilcoxon rank sum tests were 
used for comparison of continuous variables. Fisher’s exact tests were used for comparison of 
categorical variables. Interobserver agreement was quantified by Cohen’s kappa coefficient. A 
two-sided alpha error of 0.05 was used for all statistical tests, and statistical analyses were 




Clinical Characteristics and Outcome 
 
Clinical features of the 49 patients at the time of initial diagnosis are summarized in Table I and 
detailed in Supplemental Table 2. The median age was 37 years (range 19-82), with a 
male:female ratio of 1:2.3. Since many patients had been included in the previously described 
cohort of 63 patients (23), we found similar outcomes to that study including a high rate of 
primary induction failure, with seven cases with progressive disease during chemotherapy (14%) 
and two with treatment-related mortality (4%). After an overall median follow up of 78 months, 
12 patients (24%) had relapsed or refractory disease (median 5.9 months after diagnosis) and 11 
(22%) had died (median 15.9 months after diagnosis). The 5-year PFS was 70% (95% CI: 55-
81%), and the 5-year OS was 76% (95% CI 60-86%). Longer PFS was associated with limited 
stage disease (p<0.001), low/intermediate Revised International Prognostic Index (R-IPI) score 
of 0-2 (p<0.001, Figure 2C), and female sex (p=0.039). Other clinical factors, including bulky 
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The histopathologic features of the 49 cases are summarized in Table II and detailed in 
Supplemental Table 3. All cases expressed CD45, CD19 and CD20, although occasional cases 
(2-6%) showed low expression of one of these markers (Figure 1A-B). Other pan-B-cell 
markers, including BOB.1, CD22, CD79a, OCT2 and PAX5, were widely expressed, with a 
subset of cases showing low overall expression and rare cases (2-4%) showing no expression of 
one or more of these markers. CD23 expression was present in 66% of cases (Figure 1C). CD30 
was expressed in 78% of cases, with approximately half of cases showing high staining and the 
remainder showing low overall staining (Figure 1D). CD15 was weakly (1+ intensity score) 
and/or focally (1+ frequency score) expressed by tumor cells, yielding low overall staining in 
25% cases, and showed high overall staining by tumor cells in three cases (6%), typically in a 
paranuclear dot-like pattern (Figure 1E-F). Such expression was confirmed to be on tumor cells, 
and not on background macrophages, by examination under 100x magnification and determining 
the positively-stained cells to be large lymphoid cells based on their morphology on hematoxylin 
counterstain (Figure 1E inset). Ten cases demonstrated both low overall CD15 expression and 
some degree of staining for CD30 (7 high and 3 low overall CD30 expression). Of the three 
cases with high overall CD15 staining, two showed low and one showed high overall 
coexpression of CD30, while all three exhibited high staining of the pan-B-cell markers CD19, 
CD20 and PAX5. Only 26% of cases were positive for CD10, while most cases (93%) expressed 
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MUM1. High overall BCL2 expression was present in 64% of cases, but MYC/BCL2 double-
expression, using cutoffs of ≥40% for MYC and ≥50% for BCL2 as previously described (27), 
was present in only six cases (14%). PDL1 was expressed by tumor cells in 71% of cases. PD1 
was weakly and focally expressed by microenvironmental tumor-infiltrating lymphocytes in only 
two cases (5%). In cases lacking PDL1 expression on tumor cells, some showed staining of rare 
scattered background immune cells but significant microenvironmental PDL1 expression was not 
seen. Flow cytometry results were available for 15 cases (31%), eight of which (53%) 
demonstrated monoclonal surface immunoglobulin light chain expression, while the remainder 
lacked surface immunoglobulin expression. 
 
Association of Immunohistochemical Features with Outcome 
 
On univariate analysis, high overall PDL1 staining (H-score 4-12) was associated with longer 
PFS (p=0.011), while negative/low overall MUM1 staining (H-score 0-3) was marginally 
associated with longer PFS (p=0.065) (Figures 1G-L and 2A). The association between PDL1 or 
MUM1 expression and OS did not reach statistical significance (p>0.05). Expression of CD15, 
CD30, Ki67, MYC, combined MYC/BCL2 double-expression, and Hans classifier cell-of-origin 
were also not associated with outcome in terms of staining intensity, frequency or overall score. 
Dual expression of CD15 and CD30 was not associated with outcome. 
 
We developed a biologic risk score by combining the two biomarkers whose overall staining 
scores were most strongly associated with PFS on univariate analysis, assigning one point each 
for negative/low PDL1 and high MUM1 overall staining, both factors associated with increased 
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risk. The combined PDL1/MUM1 biologic risk score stratified the 46 patients for whom results 
of both stains were available into three prognostic groups for PFS (p=0.001) and OS (p=0.032): 
patients with scores of 0 and 1 had better survival (median PFS not reached) vs. those with a 
score of 2 (median PFS 28 months) (Figure 2B). On multivariable Cox proportional hazards 
model analysis (Supplemental Table 4), negative/low PDL1 staining was independent of the R-
IPI risk group for PFS (hazard ratio [HR] 6.0, p=0.023, 95% CI 1.3-27.9). In a separate model, 
the combined PDL1/MUM1 biologic risk score and R-IPI were independent predictors for PFS: 
biologic risk score of 2 vs. 0-1, HR 5.6 (p=0.011, 95% CI 1.5-21.5) and R-IPI >2 vs. 0-2, HR 9.9 
(p<0.001, 95% CI 2.7-36.0).  
 
Incorporation of the biologic risk score into traditional clinical risk stratification showed the 
biologic risk score to be prognostic within R-IPI groups for both PFS (p<0.001, Figure 2D) and 
OS (p<0.001, data not shown). Within the low to intermediate (0-2) R-IPI group that included 
the majority of patients (85%), those with a biologic risk score of 2 had an inferior PFS at 5 years 
(58%, 95% CI 27-80%) vs. those with a biologic risk score of 0-1 (92%, 95% CI 70-98%) 
(p=0.012). Among the seven patients with R-IPI >2, five (71%) had a biologic risk score of 2, all 
of whom had died within a year of diagnosis, while one of the two patients with a biologic risk 




We performed a detailed immunohistochemical characterization of a large group of PMBL and 
identified an immunophenotypic spectrum within this DLBCL subtype, including variable CD15 
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expression in a subset of cases. Correlation of immunophenotypic features with outcome in our 
uniformly-treated cohort showed that prognostic biomarkers traditionally used in DLBCL-NOS 
have limited relevance in PMBL and that CD15 expression in otherwise typical PMBL does not 
portend an adverse outcome. Finally, we developed a novel biologic risk score for PMBL, 
incorporating staining for MUM1 and PDL1, that appears to stratify patients within traditional R-
IPI subgroups and that may have clinical utility in identifying high-risk patients.   
 
Our findings largely reflect the immunohistochemical profile previously described in PMBL, 
including retained pan-B-cell antigen expression in almost all cases and frequent expression of 
CD23, CD30, MUM1 and PDL1 (1, 29, 30). Nearly one-third of cases showed some degree of 
CD15 expression in tumor cells, a feature thought to be uncommon in PMBL (1, 31). Our 
findings suggest that weak or focal CD15 staining may be more frequent in PMBL than 
previously thought, and that occasional cases of otherwise typical PMBL (e.g., those with 
DLBCL-like morphology and retained pan-B-cell antigen expression) may show moderate or 
even strong CD15 expression that is typically in a paranuclear dot-like pattern. However, CD15 
expression in our PMBL cohort, both alone and in combination with CD30 expression, was not 
associated with adverse clinical outcome, in contrast to what has been suggested for MGZL with 
CD15 expression (31). Our findings point to the need for employing strict criteria in rendering a 
diagnosis of MGZL, and suggest that cases of otherwise typical PMBL with CD15 co-expression 
should not be diagnosed as MGZL, unless additional features of CHL-like morphology or pan-B-
cell antigen loss are present. 
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We studied a number of immunohistochemical markers previously found to be prognostic in 
DLBCL-NOS, including germinal center vs. non-germinal center cell-of-origin (25), Ki67 
proliferation index (32), high MYC expression (33), and double-expression of MYC and BCL2 
(27, 34), using commercial antibodies routinely available for clinical diagnostic use. None of 
these biomarkers was associated with outcome in our series, suggesting that 
immunohistochemical prognostic markers of DLBCL-NOS are not applicable to PMBL. We 
identified two potential PMBL-specific biomarkers, low PDL1 and high MUM1 expression, as 
being most strongly associated with an adverse outcome on univariate analysis. By combining 
both biomarkers into a PDL1/MUM1 biologic risk score ranging from 0-2, we were able to 
stratify patients into three prognostic groups with good, intermediate and poor survival and sub-
stratify patients within the low to intermediate R-IPI subgroup. The biologic risk score retained 
its significance independently of the R-IPI on multivariate analysis for PFS. Our findings suggest 
that immunohistochemical evaluation of PDL1 and MUM1 at the time of initial PMBL diagnosis 
may enhance traditional clinical risk stratification and may be useful to prognosticate and predict 
response to R-CHOP chemotherapy, as well as to identify patients who may benefit from more 
intense regimens such as dose-adjusted R-EPOCH. Additional studies are needed to validate 
these results, particularly in a prospective setting. 
 
High MUM1 expression has been associated with an inferior outcome in DLBCL-NOS, likely 
due to the role of the MUM1 gene, IRF4, in lymphocyte activation and proliferation in the 
terminal stages of B-cell differentiation into plasma cells (25, 35, 36). However, the biologic 
mechanism by which low PDL1 expression might contribute to an adverse clinical outcome in 
PMBL is uncertain. PMBL has been associated with a more favorable outcome than DLBCL-
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NOS (4), and PDL1 expression is more frequent in PMBL than in other DLBCL subtypes (28). 
Therefore, the adverse outcome seen in PMBL with low PDL1 expression may reflect tumor 
biology more similar to DLBCL-NOS than to classic PMBL. 
 
In many malignancies, high PDL1 expression is associated with a poor prognosis due to its 
downregulation of the host anti-tumor immune response through interaction with PD1 on 
effector T cells (37). In one study of a heterogeneous group of DLBCL, including some cases of 
PMBL, increased PDL1 expression (defined as ≥30% staining of lymphoma cells) was 
associated with inferior OS (28). However, there is little prior data on the association of PDL1 
expression with outcome in a pure cohort of uniformly treated PMBL. One study of 27 cases of 
non-uniformly treated PMBL found no association between PDL1 staining and outcome using a 
cutoff of 30% positivity (38). Similarly, in another study of 51 cases using a cut-off of 5% 
positivity, there was no association between PDLI staining and outcome, although treatment data 
were not reported (39). In contrast to these prior studies, our cohort was restricted to cases of 
PMBL that were uniformly treated, and other DLBCL subtypes were excluded. 
 
As in PMBL, the Reed-Sternberg cells of CHL demonstrate high PDL1 expression. The tumor-
infiltrating T cells in CHL express PD1 with high frequency, providing a rationale for 
PDL1/PD1-mediated immune escape in CHL and therapeutic PD1 blockade (40, 41). In contrast 
to CHL, we and others have found PD1 to be infrequently expressed on tumor-infiltrating 
lymphocytes in PMBL (42), suggesting that PDL1/PD1-mediated immune escape may be less 
important for tumor cell survival in PMBL than in other malignancies with a higher frequency of 
PD1-positive background inflammatory cells. Moreover, the role of PDL1 and PD1 in immune 
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evasion may differ between tumor types and remains to be fully elucidated in lymphomas. 
Indeed, increased numbers of PD1-positive tumor infiltrating lymphocytes have been shown to 
be a favorable prognostic feature in follicular lymphoma, suggesting that PDL1/PD1 interactions 
may operate indirectly via inhibition of pro-tumor microenvironmental inflammatory responses 
in some lymphoma subtypes (42-44). 
  
In summary, we characterize the immunophenotypic spectrum of PMBL and demonstrate that 
CD15, a marker traditionally associated with MGZL and CHL, may be expressed in a subset of 
PMBL, although expression is usually weak or focal in most such cases. CD15 expression does 
not appear to negatively impact prognosis, even in cases where expression is strong or diffuse or 
when CD30 is co-expressed. Although immunohistochemical markers with prognostic utility in 
DLBCL-NOS appear to lack relevance in PMBL, we identify PDL1 and MUM1 as two potential 
PMBL-specific biomarkers. We demonstrate that a biologic risk score incorporating these two 
stains, both of which are widely available for routine diagnostic use, is independent of clinical 
risk stratification by R-IPI and can sub-stratify patients within R-IPI groups, particularly those 
considered low-to-intermediate risk. Additional studies are needed to validate the utility of this 
biologic risk score in identifying higher-risk patients who may benefit from intensified or novel 
treatment approaches. 
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Figure 1: Immunophenotypic spectrum and expression of MUM1 and PDL1 in PMBL. A-
D: An example of PMBL (A, H&E) with typical immunophenotypic features of high overall 
expression of CD20 (B), and some expression of CD23 (C) and CD30 (D). E-F: CD15 was 
weakly or focally expressed in tumor cells of a minority of cases (E and inset) and showed 
moderate or strong overall staining of many tumor cells in rare cases (F). G-L: Examples of two 
PMBL cases, one (G, H&E) showing no/low overall MUM1 staining (H) and high overall PDL1 
staining (I), and another (J, H&E) showing high overall MUM1 staining (K) and no/low overall 
PDL1 staining (L).  
 
Figure 2: Kaplan-Meier curves of progression-free survival. Association with PDL1 
expression (H-score 0-3 vs. 4-12) (A); combined PDL1/MUM1 biologic risk score ranging from 
0-2 with one point each for negative or low overall PDL1 (H-score 0-3) and high overall MUM1 
(H-score 4-12) (B); R-IPI alone (C); and R-IPI (0-2 vs. >2) with incorporation of PDL1/MUM1 
biologic risk score (0-1 vs. 2) (D). Tables below each curve represent number of patients at risk 
at each time point. 
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Median 37 (range 19-82) 
 
Over 60 5 (10%) 
Female gender (n=49) 34 (69%) 
Ann Arbor Stage (n=49) 
 
 
I 18 (37%) 
 
II 21 (43%) 
 
III 1 (2%) 
 
IV 9 (18%) 
Elevated LDH (n=43) 36 (84%) 




Low to Intermediate (0-2) 41 (85%) 
 
High (>2) 7 (15%) 
Mediastinal mass median size (cm; n=42) 11 (range 5-20) 
 
Mass size ≥ 10 cm 29 (69%) 
Any non-contiguous extranodal disease (n=46) 15 (33%) 
 
>1 non-contiguous extranodal site (n=45) 7 (16%) 
Median number of R-CHOP cycles 6 (1-8) 
Consolidative radiation in responding patients (n=48) 35 (73%) 
*Clinical and outcome data on a major subset of this cohort have been reported previously.
23
 
LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; R-IPI, revised 
International Prognostic Index; R-CHOP, rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone.  
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Table II. Immunohistochemical  features of PMBL 
  









    
Pan-B-cell 
markers 
BOB.1 44 (92) 2 (4) 2 (4) 
CD19 45 (94) 3 (6) 0 
CD20 47 (98) 1 (2) 0 
CD22 33 (67) 14 (29) 2 (4) 
CD23   18 (37) 14 (29) 17 (35) 
CD45 47 (98) 1 (2) 0 
CD79a 35 (73) 12 (25) 1 (2) 
OCT2 39 (81) 7 (15) 2 (4) 
PAX5 46 (96) 1 (2) 1 (2) 
     
Hodgkin 
markers 
CD15 3 (6) 12 (25) 33 (69) 
CD30 19 (40) 18 (38) 11 (23) 
 
    
Hans 
classifier 
CD10 6 (14) 5 (12) 32 (74) 
BCL6 27 (61) 15 (34) 2 (5) 
MUM1 36 (73) 10 (20) 3 (6) 
     
 
BCL2 28 (64) 12 (27) 4 (9) 
     
 
PDL1 20 (43) 13 (28) 13 (28) 
 
PD1 0 2 (5) 39 (95) 
     
  
Average Range ≥40%, N (%) 
 
Ki67 (%) 32 0-100 17 (38) 
 
MYC (%) 28 0-70 16 (34) 
         
     
Cell of 
origin 
Germinal center: 10 (23%) 
 Non-germinal center: 33 (77%) 
 Not evaluable: 6 
 
     
BCL2/MYC 
Double-expressing: 6 (14%) 
 Non-double-expressing: 38 (86%) 
 Not evaluable: 5 
 
     Overall score: High or Moderate/Strong/Diffuse (H-score 4-12), Low or Weak/Focal (H-
score 1-3), Negative (H-score 0). PD1 staining of tumor-infiltrating lymphocytes. Cell of 
origin based on the Hans classifier.
25
 Double-expression defined as ≥40% MYC and ≥50% 
BCL2 staining.
27 
Total N is less than 49 for some stains because some antibodies were not 
evaluable for all cases. 
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Figure 1: Immunophenotypic spectrum and expression of MUM1 and PDL1 in PMBL. A-D: An example of 
PMBL (A, H&E) with typical immunophenotypic features of high overall expression of CD20 (B), and some 
expression of CD23 (C) and CD30 (D). E-F: CD15 was weakly or focally expressed in tumor cells of a 
minority of cases (E and inset) and showed moderate or strong overall staining of many tumor cells in rare 
cases (F). G-L: Examples of two PMBL cases, one (G, H&E) showing no/low overall MUM1 staining (H) and 
high overall PDL1 staining (I), and another (J, H&E) showing high overall MUM1 staining (K) and no/low 
overall PDL1 staining (L).  
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Figure 2: Kaplan-Meier curves of progression-free survival. Association with PDL1 expression (H-score 0-3 
vs. 4-12) (A); combined PDL1/MUM1 biologic risk score ranging from 0-2 with one point each for negative or 
low overall PDL1 (H-score 0-3) and high overall MUM1 (H-score 4-12) (B); R-IPI alone (C); and R-IPI (0-2 
vs. >2) with incorporation of PDL1/MUM1 biologic risk score (0-1 vs. 2) (D). Tables below each curve 
represent number of patients at risk at each time point.  
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